| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
|
Still deciding? Get samples of US$ 50/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name: | Afatinib (BIBW 2992);Gilotrif |
| Synonyms: | BIBW 2992;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;Tovok;Tovok, BIBW 2992;BIBW2992 Afatinib;Afatinib (BIBW 2992);ToMtovok;(S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide |
| CAS: | 439081-18-2 |
| MF: | C24H25ClFN5O3 |
| MW: | 485.944 |
| Purity: | 99.5% min |
| Appearance: | White or Nearly White Crystalline Powder |
| MOQ: | 10G |
| Specifications: | Pharmaceutical Grade |
| Deliver time: | About 5 days |
| Deliver methods: | TNT,EMS,HKEMS,DHL,ect.(door to door) |
1.Afatinib is pronounced aff-a-tin-ib. It has the brand name Giotrif (jee-oh-triff). It is a type of biological therapy called a tyrosine kinase inhibitor (TKI). It is a treatment for non small cell lung cancer that has spread outside the lung or to other parts of the body.
2.It has received regulatory approval for use as a treatment for non-small cell lung cancer,although there is emerging evidence to support its use in other cancers such as breast cancer.
3. How afatinib works:
This type of drug works by blocking particular proteins on cancer cells that encourage the cancer to grow. Afatinib blocks proteins called epidermal receptors (EGFR). Cancers that have these receptors are called EGFR positive.
Between 10 and 15 people out of every 100 with non small cell lung cancer (10 to 15%) have EGFR positive cancer. Doctors check your cancer cells to see if they have the receptors before you have this treatment.
Afatinib may shrink the cancer or stop it growing for a time
4. Uses and fuction:
Afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer) that has spread to other parts of the body. It belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal receptor-EGFR) in some tumors.
5. Mechanism of action:
Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits human epidermal receptor 2 (Her2) and epidermal receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation tyrosine-kinase inhibitors (TKIs) likeerlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies.Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.
COA:
| Item | Requirements | Test Results |
| Description | Off-white powder | Off-white powder |
| Identification | HPLC ,NMR | Complies |
| Residue on Ignition | ≤0.10% | 0.05% |
| Loss on Drying | ≤0.50% | 0.15% |
| Heavy Metal | ≤20ppm | <20ppm |
| Purity(HPLC) | ≥99.0% | 99.99% |
| Conclusion | It complies with EnterpriseStandard | |
){kind=link}